For example, ongoing clinical trials are targeting the cyclic nucleotide-gated cation channel alpha-3 (CNGA3) and beta-3 (CNGB3) genes responsible for achromatopsia, with early results indicating safety and potential efficacy (14). This evidence concerns the gene CNGA3 and achromatopsia.